CJC-1295/Ipamorelin: Growth hormone–releasing peptides that promote fat loss, muscle growth, deeper sleep, and anti-aging.

⭐⭐⭐⭐⭐Boosts Growth Hormone 5x

Potential Benefits of CJC-1295 + Ipamorelin

Physiologic GH Support

Combines a GHRH analogue (CJC-1295) with a ghrelin-receptor agonist (Ipamorelin) to encourage pulsatile growth-hormone release rather than direct GH replacement.

Sleep, Recovery & Vitality

Commonly used in programs that target deeper sleep, post-training recovery, and general vitality—paired with nutrition and training.

Body-Composition Support

When combined with diet and exercise, may assist lean-mass maintenance and fat-loss efforts.

Important: Compounded peptides are off-label for adults and not FDA-approved for anti-aging or weight loss. Human evidence is limited. Use only under supervision of a licensed clinician.

Contraindications & Precautions

Contraindications

• Known hypersensitivity to CJC-1295, Ipamorelin, or formulation excipients

• Pregnancy or breastfeeding

• Active malignancy (or history of cancer without verified remission)

Use with Caution

• Diabetes or impaired glucose tolerance — clinician may monitor glucose/A1c

• Thyroid or pituitary disorders — specialist oversight recommended

• Cardiovascular, hepatic, or renal disease — coordinate with prescriber

• Fluid-retention symptoms (edema, carpal-tunnel-like paresthesia) — adjust or discontinue if needed

• Concurrent GH-axis therapies or weight-management drugs — avoid stacking without guidance

Results, Dosing & Side Effects

Typical Program Goals

• Support healthier sleep architecture and recovery

• Assist body-composition plans alongside diet and exercise

• Promote wellbeing/energy when clinically appropriate

• Individualized targets set by clinician and labs

Dosing & Administration

• Route: Subcutaneous injection (often evening); rotate abdomen/thigh/upper arm sites

• Schedule: Nightly or cyclical protocols per clinic; some combine both peptides in one session

• Monitoring: Clinician may track IGF-1, metabolic markers, sleep metrics, and symptoms

Exact dose and frequency are individualized. Follow your provider’s instructions.

Side Effects — Common

• Injection-site redness/itching or bruising

• Flushing, lightheadedness, headache

• Nausea, transient fatigue, vivid dreams

• Temporary water retention, joint/tunnel-like tingling

• Appetite changes (ghrelin-related with Ipamorelin)

Side Effects — Monitor/Serious

• Worsening glucose control — contact your provider

• Significant edema, palpitations, or chest pain — evaluate promptly

• Allergic reactions (rash, swelling, breathing difficulty) — seek care

Why Choose CJC-1295 + Ipamorelin?

This combo engages two complementary GH pathways: CJC-1295 (GHRH analogue) cues the pituitary to release GH in a physiologic, pulsatile manner, while Ipamorelin (ghrelin-receptor agonist) enhances that signal with minimal cortisol/prolactin overlap compared to older secretagogues.

Patient Story:
“Within a few weeks, my sleep felt deeper and workouts recovered faster. Pairing the injections with a clean diet made the difference.” — Avery S.

Mechanism of Action

• GHRH Receptor Agonism (CJC-1295): Stimulates pituitary GH release; encourages downstream IGF-1 in a physiologic pattern

• Ghrelin Receptor Agonism (Ipamorelin): Amplifies GH pulses with selective pituitary action

• Pulsatility: Seeks to preserve natural GH rhythm vs. flat replacement

• Program Fit: Best used with sleep hygiene, resistance training, protein-forward nutrition, and clinician monitoring

Educational content only. Peptide programs should be supervised by a licensed healthcare professional and individualized to the patient.